| 18/10/21 | 07:00:06 | 18 Oct 2021 | | AZ recommends ADS holders reject mini-tender offer |
| 15/10/21 | 07:00:03 | 15 Oct 2021 | | Imfinzi & tremelimumab improved OS in liver cancer |
| 11/10/21 | 07:00:10 | 11 Oct 2021 | | AZD7442 PhIII trial positive in COVID outpatients |
| 04/10/21 | 07:00:07 | 4 Oct 2021 | | Enhertu granted BTD for breast cancer |
| 01/10/21 | 15:00:02 | 1 Oct 2021 | | Total Voting Rights |
| 30/09/21 | 16:00:07 | 30 Sept 2021 | | Director/PDMR Shareholding |
| 29/09/21 | 07:00:09 | 29 Sept 2021 | | AstraZeneca to fully acquire Caelum Biosciences |
| 28/09/21 | 07:00:05 | 28 Sept 2021 | | Saphnelo approved in Japan for SLE |
| 24/09/21 | 07:00:05 | 24 Sept 2021 | | Lynparza PROpel trial meets primary endpoint |
| 23/09/21 | 07:00:08 | 23 Sept 2021 | | Board Committee Change |
| 23/09/21 | 07:00:08 | 23 Sept 2021 | | New Sustainability Committee of the Board |
| 21/09/21 | 07:00:09 | 21 Sept 2021 | | AstraZeneca $360m Irish manufacturing investment |
| 20/09/21 | 07:00:08 | 20 Sept 2021 | | Enhertu reduced risk of disease progression by 72% |
| 09/09/21 | 16:00:04 | 9 Sept 2021 | | Imfinzi improves survival in NSCLC in POSEIDON |
| 09/09/21 | 07:00:05 | 9 Sept 2021 | | PT027 PhIII asthma trials met primary endpoints |
| 03/09/21 | 07:00:06 | 3 Sept 2021 | | Ultomiris approved in EU for children with PNH |
| 01/09/21 | 15:00:06 | 1 Sept 2021 | | Total Voting Rights |
| 26/08/21 | 07:05:00 | 26 Aug 2021 | | Forxiga approved in Japan for CKD |
| 26/08/21 | 07:00:02 | 26 Aug 2021 | | ALXN1840 Wilson Phase III met primary endpoint |
| 20/08/21 | 07:05:04 | 20 Aug 2021 | | Update on Ultomiris Phase III ALS trial |
| 20/08/21 | 07:00:09 | 20 Aug 2021 | | AZD7442 prophylaxis trial met primary endpoint |
| 16/08/21 | 15:00:01 | 16 Aug 2021 | | Director/PDMR Shareholding |
